


Talking Time: Participant flow diagram



Talking Time: Baseline characteristics

Setting level (categorical)	Talking Time		Control group	
	n/N (missing)	Count (%)	n/N (missing)	Count (%)
PVIs	62/62 (0)	19%	61/61 (0)	19%
Setting level (continuous)	n/N (missing)	Mean (SD)	n/N (missing)	Mean (SD)
IDACI score	62/62 (0)	0.23 (0.11)	61/61 (0)	0.23 (0.11)
Child level (categorical)	n/N (missing)	Count (%)	n/N (missing)	Count (%)
EYPP-eligible	165/852 (20)	19%	143/809 (24)	19%
EAL	277/864 (8)	34%	272/825 (8)	35%
Child level (categorical)	n/N (missing)	Mean (SD)	n/N (missing)	Mean (SD)
Female	435/872 (0)	0.49 (0.50)	420/833(0)	0.49 (0.50)
Child level (continuous)	n/N (missing)	Mean (SD)	n/N (missing)	Mean (SD)
Age in months	872 (0)	42.9 (4.0)	833 (0)	42.9 (4.1)
Renfrew assessment index (primary outcome)	817/872 (55)	13.6 (6.8)	796/833 (37)	13.2(6.8)
REV assessment (expressive vocabulary)	829/872 (43)	17.8 (9.5)	809/833 (24)	17.6 (9.6)
RAPT assessment (vocabulary knowledge)	858/872 (14)	14.0 (6.9)	820/833 (13)	13.3 (6.8)
RAPT assessment (grammar)	858/872 (14)	8.6 (6.2)	820/833 (13)	8.3 (6.1)
GAPS assessment	796/872 (76)	3.5 (4.0)	749/833 (84)	3.4 (3.9)

Talking Time: Impact on the primary outcome

Outcome	Unadjusted means				Effect size		
	Intervention group		Control group				
	n (missing)	Mean (95% CI)	n (missing)	Mean (95% CI)	Total n (intervention; control)	Hedges' g (95% CI)	P-value
Renfrew composite index	725 (0)	1.15 (1.09,1.22)	714 (0)	0.99 (0.92,1.06)	1,439	0.083 (0.001, 0.164)	0.047

Talking Time: Impact on the secondary outcomes

Outcome	Unadjusted means				Effect size		
	Intervention group		Control group				
	n (missing)	Mean (95% CI)	n (missing)	Mean (95% CI)	Total n (Intervention; control)	Hedges' g (95% CI)	P-value
REV	734 (95)	27.61	725 (84)	26.38	1,459	0.079 (0.002, 0.157)	0.044
RAPT information (vocabulary knowledge)	772 (86)	21.60	745 (75)	20.53	1,517	0.064 (-0.014, 0.142)	0.248
RAPT grammar	772 (86)	15.57	745 (75)	14.74	1,517	0.092 (-0.20, 0.203)	0.107
GAPS test	701 (95)	6.93	668 (81)	7.09	1,369	-0.054 (-0.136, 0,028)	0.194

There were no adverse events associated with this study.